Partnership combines Inocras’s clinical grade cancer diagnostics and analytics solutions with NDS’s cloud and secure data environment infrastructure
Inocras, a bioinformatics-driven company specializing in whole-genome data analytics, has announced a strategic partnership with NDS Corporation, a South Korean IT services provider focused on healthcare data and cloud solutions. The collaboration aims to jointly develop and commercialize cloud-based genomic analysis platforms designed to help healthcare providers operationalize whole-genome sequencing for cancer care. The announcement was made alongside the HIMSS Conference held March 9–12, 2026, in Las Vegas, Nevada.
As precision medicine and AI in healthcare continue transforming cancer diagnosis and treatment, whole-genome sequencing has become increasingly valuable in identifying patient-specific genetic mutations. However, managing and analyzing the vast datasets generated by genomic sequencing requires advanced bioinformatics capabilities and scalable cloud infrastructure. Through this partnership, Inocras and NDS aim to address these challenges by delivering a secure, cloud-native genomic platform tailored for clinical environments.
Health Technology Insights: https://healthtechnologyinsights.com/russias-cancer-vaccine-is-a-new-breakthrough-in-health-technology/
The joint solution will combine Inocras’s expertise in whole-genome cancer analytics and clinical interpretation with NDS’s cloud platform development and healthcare IT infrastructure capabilities. Together, the companies will enable healthcare institutions to analyze complex genomic datasets efficiently while maintaining clinical-grade performance, security, and regulatory compliance.
Jehee Suh, Chief Executive Officer of Inocras, emphasized the importance of scalable genomic infrastructure in modern oncology care. He noted that the partnership represents a critical step toward making whole-genome analysis operationally feasible for healthcare organizations. By integrating advanced genomic analytics with secure cloud environments, medical institutions can process large cancer genome datasets while advancing personalized treatment strategies for patients.
Under the collaboration framework, NDS will lead the development and implementation of the cloud infrastructure supporting the genomic analysis platform. This includes building scalable environments, ensuring system reliability, and providing ongoing technical support. Inocras will contribute its proprietary genomic analytics technology, clinical interpretation expertise, and consultation services to support pilot deployments and commercialization efforts.
Joong Won Kim, Chief Executive Officer of NDS Corporation, highlighted the strategic value of combining the two companies’ capabilities. By integrating NDS’s cloud and healthcare platform expertise with Inocras’s genomics analytics, the partnership aims to develop infrastructure solutions suitable for both clinical and research environments. The companies also plan to expand joint deployments across global markets, including North America.
Health Technology Insights: https://healthtechnologyinsights.com/cloud-platforms-and-infrastructure-modernization-in-health-tech/
The platform will deliver several benefits for healthcare organizations seeking to integrate genomic medicine into routine care. These include clinical-grade whole-genome sequencing capabilities designed to handle large cancer datasets, improved operational efficiency through cloud-native automation, and streamlined workflows that align with hospital and laboratory processes.
Security and compliance are also central to the platform design. The infrastructure is intended to support highly regulated clinical and research environments, ensuring that genomic data is processed and stored with strong security protections.
A key component of the platform strategy involves transitioning from traditional server management to an automated cloud-native model using AWS HealthOmics. This approach allows healthcare institutions to analyze large-scale genomic datasets without maintaining permanent on-premise infrastructure, significantly reducing operational complexity while improving scalability.
By combining advanced bioinformatics analytics, cloud computing infrastructure, and AI-driven genomic insights, the partnership between Inocras and NDS represents a major step forward in bringing whole-genome sequencing into routine clinical oncology care.
Health Technology Insights: https://healthtechnologyinsights.com/aws-expands-cloud-and-ai-capabilities-for-healthcare-providers/
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
